Turn small steps into big wins.

The FreeStyle Libre systems let you see your glucose levels in real time* and help you make small changes that can lower your A1C†1.

This is Progress.

Man wearing a FreeStyle Libre continuous glucose monitoring (CGM) sensor checking his blood glucose
Man wearing a FreeStyle Libre continuous glucose monitoring (CGM) sensor checking his blood glucose
Man wearing a FreeStyle Libre continuous glucose monitoring (CGM) sensor checking his blood glucose

#1 CGM prescribed for Medicare patients‡§2,3

Manage your diabetes more confidently†4 with the FreeStyle Libre 3 or FreeStyle Libre 2 systems. They’re covered by Medicare for people managing diabetes with insulin‡2.
Ask your healthcare provider about the FreeStyle Libre 3 or FreeStyle Libre 2 system, if you take insulin for your diabetes.

CGM = continuous glucose monitor(ing)

 

 
 

Significantly lower your A1C†1,‖5, without fingersticks.

The FreeStyle Libre 3 and FreeStyle Libre 2 systems are CGM systems that allow you to know your glucose levels anytime#, anywhere** for up to 15 days with a single sensor6,7.

Easy to apply and wear8 with no fingersticks required

Real-time glucose readings are automatically†† sent to your reader‡‡ or smartphone§§ every minute, without scanning

The world’s smallest, thinnestIIII, and most discreet3 sensor

Real-time glucose readings with a painless†9 scan using your reader¶¶ or smartphone§§

Alarms## trigger when glucose readings cross your customized levels***

The FreeStyle Libre 2 Plus sensor lasts for up to 15 days7

Find out if you’re eligible.

If you have Medicare, you may be covered for the FreeStyle Libre 3 or 2 system if you meet all of the following coverage criteria2:

You have been diagnosed with diabetes.

Your doctor has determined that you (or your caregiver) have adequate training using a CGM and has written a prescription.

Your CGM is being used as indicated by the FDA.

When it comes to treating your glucose, you use insulin or have a history of problematic hypoglycemia (including multiple level 2 events, or at least one level 3 event).

You have seen your doctor within 6 months prior to starting CGM to evaluate your diabetes management and confirm you meet all coverage criteria.

Still not sure if you’re covered for the FreeStyle Libre 3 system or FreeStyle Libre 2 system? Reach out to our customer care team to learn more about the #1 prescribed CGM system in the US†††. The team is available 7 days a week from 8 AM to 8 PM Eastern Time, excluding holidays.

CGM = continuous glucose monitor(ing)

Contact your doctor to get a prescription.

Ask your healthcare provider if you qualify for the FreeStyle Libre 3 or FreeStyle Libre 2 system through Medicare. Your prescription must include both the reader‡‡¶¶ and the sensors to be eligible for Medicare coverage.

Use our discussion guide to help start the conversation.

MyFreeStyle

MyFreeStyle was created to help people like you manage their diabetes and get started with the FreeStyle Libre 3 or FreeStyle Libre 2 system.

Help stay on top of your diabetes. management at no cost to you.

Learn how to apply
and start your sensor.

See how food and exercise
affect your glucose levels.

Sign up for MyFreeStyle today!

This form is only for Medicare patients.

If you do not have Medicare, please click here.

To proceed, please fill in or correct the field(s) in this form.

Who are you signing up for the MyFreeStyle program?

 
Please select one so we can personalize your experience.

Which sensor are you interested in?

 
Please select a product.

Your Information

 
Please select.
Please provide your first name. Please provide your first name. Please provide your first name.
Please provide your last name. Please provide your last name. Please provide your last name.
Please provide a valid email address. Looks like something isn't right. Please try again with a valid email address.
Please provide a valid mobile phone number.

Patient's Information

Please provide the patient's first name. Please provide the patient's first name. Please provide the patient's first name.
Please provide your first name. Please provide your first name. Please provide your first name.
Please provide the patient's last name. Please provide the patient's last name. Please provide the patient's last name.
Please provide your last name. Please provide your last name. Please provide your last name.
Please provide a valid email address. Looks like something isn't right. Please try again with a valid email address.
Please provide the patient's date of birth.
Please provide the patient's date of birth
Please provide your date of birth.
Please provide your date of birth
Please provide a valid mobile phone number.
Please provide a valid ZIP code. Please provide a valid ZIP code. Please enter valid Zip code.
 
Please select.
 
Please select.

By submitting this form you are agreeing that Abbott may send you non-promotional communications, informational and promotional emails about our products and services and/or associated conditions and treatments, in addition to any messaging you may have opted into above in accordance with our Abbott Privacy Policy.

Have questions? We have answers!
 

Is the FreeStyle Libre 3 system covered for Medicare beneficiaries?

Is the FreeStyle Libre 2 system covered for Medicare beneficiaries?

Can I pay cash for the FreeStyle Libre 2 system if it is not covered by my insurance? How much would I be paying?

Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.

* 60-minute warm-up required when starting the sensor.

† Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.

‡ Patients must meet Medicare eligibility coverage criteria.

§ Data based on total active Medicare patients with CGM readers.

‖ Study was performed with the outside US version of the FreeStyle Libre 2 system. Data is applicable to FreeStyle Libre 2 and FreeStyle Libre 3 systems, as feature sets are similar.

¶ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.

# Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or "LO" or "HI" message, or no current glucose reading.

** Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

†† The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.

‡‡ The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

§§ The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.

IIII Among patient-applied sensors.

¶¶ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

## Notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2 system) or 33 feet (FreeStyle Libre 3 system) unobstructed of the reading device.

*** The FreeStyle Libre 2 app also has a mandatory Urgent Low Glucose Alarm that lets users know when their glucose value is below 55mg/dL.

††† Based on retail and DME sales data for the patient’s last-filled prescription, by manufacturer.

‡‡‡ Participating pharmacies and durable medical equipment (DME) suppliers are subject to change without notice.

§§§ Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary.

References: 1. Evans, Mark, et al. “The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-World Observational Studies.” Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 2. Local Coverage Determination (LCD) L33822, Glucose Monitors, https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33822. 3. Data on file. Abbott Diabetes Care, Inc. 4. Fokkert, Marion, et al. "Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 5. Leelarathna, Lalantha, et al. "Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes." New England Journal of Medicine 387, no. 16 (2022): 1477-1487. https://doi.org/10.1056/nejmoa2205650. 6. FreeStyle Libre 3 User's Manual. 7. FreeStyle Libre 2 User’s Manual. 8. Alva, Shridhara, et al. "Accuracy of the third generation of a 14-day continuous glucose monitoring system." Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6. 9. Haak, Thomas, et al. “Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated Type 2 diabetes: a multicentre, open-label randomised controlled trial.” Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6.

ADC-37051 v12.0